Evidence map›Paper›PMID 29313949›Full record

ArticleCA: a cancer journal for clinicians2018

Cancer statistics, 2018.

Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal

22 registry-linked trialsOpen access · diamondAbstract read
PubMed Publisher
In one paragraph

Article in CA: a cancer journal for clinicians, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 22 registered trials, which are not on this map. Cited by 9,491 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9,491citing papers in PubMed, 13 pooled it
1219.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03498924 completednot on this map

Prospective Identification and Characterization of Endometrial Cancer With Specific Tumor Markers in Serum and Endometrial Tissue Samples

TypeobservationalSponsorFundación Investigación Sanitaria en LeónRan2017 to 2019Enrolled80ConditionsEndometrial Neoplasm MalignantArmsMeasure of biomarkers in serum and endometrial tissue
NCT03622385 completednot on this mapstarted 2019, after this paper: background citation

Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer

TypeobservationalSponsorBaylor Research InstituteRan2019 to 2021Enrolled10ConditionsEpithelial Ovarian CancerArmsDNA Methylation
NCT03706547 phase1unknown statusnot on this map

Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma

TypeinterventionalSponsorPeng LiuRan2018 to 2021Enrolled20ConditionsMultiple Myeloma in Relapse, Multiple Myeloma ProgressionArmsanti-CD19/BCMA CAR-T cells, Fludarabine, Cyclophosphamide
NCT03829930 phase1terminatednot on this mapstarted 2019, after this paper: background citation

A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer

TypeinterventionalSponsorGeorge Washington UniversityRan2019 to 2020Enrolled6ConditionsProstate AdenocarcinomaArmsEntinostat, Enzalutamide
NCT03870386 nacompletednot on this mapstarted 2019, after this paper: background citation

EUS-guided Biliary Drainage of First Intent With the Lumen Apposing Metal Stent vs. ERCP in the Management of Malignant Distal Biliary Obstruction: a Randomized Controlled Trial

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2019 to 2023Enrolled144ConditionsBiliary ObstructionArmsEUS-BD with LAMS, ERCP
NCT03923335 not yet recruitingnot on this mapstarted 2019, after this paper: background citation

The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer

TypeobservationalSponsorSixth Affiliated Hospital, Sun Yat-sen UniversityRan2019 to 2026Enrolled287ConditionsColorectal NeoplasmsArmsDNA methylation detection
NCT04025840 phase4active not recruitingnot on this mapstarted 2019, after this paper: background citation

Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery: a 2×2 Factorial Randomized Controlled Trial

TypeinterventionalSponsorPeking University First HospitalRan2019 to 2026Enrolled260ConditionsPancreatic Cancer, Surgery, Epidural Block, DexamethasoneArmsEpidural block, Dexamethasone
NCT04101292 nawithdrawnnot on this mapstarted 2021, after this paper: background citation

Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours

TypeinterventionalSponsorIHU StrasbourgRan2021 to 2023Enrolled0ConditionsColorectal CancerArmsCharacterization of tumor tissue by fluorescence
NCT04225910 early_phase1unknown statusnot on this mapstarted 2020, after this paper: background citation

Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer

TypeinterventionalSponsorXinhua Hospital, Shanghai Jiao Tong University School of MedicineRan2020 to 2021Enrolled20ConditionsMetastatic Castration-resistant Prostate CancerArms225Ac-PSMA
NCT04583072 completednot on this mapstarted 2019, after this paper: background citation

SEPTA Trial: Stockholm3 Validation Study in a Multi-Ethnic Cohort for ProsTAte Cancer

TypeobservationalSponsorKarolinska InstitutetRan2019 to 2023Enrolled2,152ConditionsProstate Cancer (Diagnosis)ArmsThe Stockholm3 test
NCT04585243 naterminatednot on this mapstarted 2020, after this paper: background citation

HPV Self-sampling Among Women at the Penn State Hershey Colposcopy Clinics

TypeinterventionalSponsorMilton S. Hershey Medical CenterRan2020 to 2022Enrolled22ConditionsHPVArmsEvalyn Brush
NCT04591977 naterminatednot on this mapstarted 2021, after this paper: background citation

HPV Self-sampling Among Women at Penn State Hershey Well Women Appointments

TypeinterventionalSponsorMilton S. Hershey Medical CenterRan2021 to 2022Enrolled46ConditionsHPVArmsHPV Self-Sampling Kit (Evalyn Brush)
NCT04658888 nacompletednot on this mapstarted 2021, after this paper: background citation

Increasing Cervical Cancer Screening Among Female Patients at Penn State Health St. Joe's Residency Clinic: Letter Notifying Them About Outdated Screen and Postcard With Self-sampling Option

TypeinterventionalSponsorMilton S. Hershey Medical CenterRan2021 to 2022Enrolled964ConditionsCervical Cancer ScreeningArmsEvalyn Self-Sampling Brush
NCT04720131 phase2completednot on this mapstarted 2021, after this paper: background citation

Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.

TypeinterventionalSponsorBeijing Friendship HospitalRan2021 to 2023Enrolled28ConditionsBiliary Tract Cancer, Anti-PD-1 Therapy, Targeted Molecular Therapy, CapecitabineArmsCamrelizumab, apatinib, Capecitabine
NCT04730999 phase2completednot on this mapstarted 2020, after this paper: background citation

A Phase II, Single Arm Study of CarbopLatin Plus Etoposide With Bevacizumab and Atezolizumab in Patients With exTEnded-disease Small-cell Lung Cancer (SCLC)

TypeinterventionalSponsorGruppo Oncologico Italiano di Ricerca ClinicaRan2020 to 2024Enrolled54ConditionsSmall Cell Lung CancerArmsEtoposide, Carboplatin, Bevacizumab, Atezolizumab
NCT05287945 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

TypeinterventionalSponsorOncorena ABRan2023 to 2027Enrolled75ConditionsCarcinoma, Renal CellArmsOrellanine
NCT05623267 phase2 / phase3recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy

TypeinterventionalSponsorSun Yat-sen UniversityRan2023 to 2027Enrolled346ConditionsLimited Stage Small Cell Lung CancerArmsSugemalimab, Placebo
NCT05707910 phase1active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

TypeinterventionalSponsorWest China HospitalRan2023 to 2027Enrolled6ConditionsMalignant TumorArmsEBV immunological agent
NCT06056791 phase1 / phase2completednot on this mapstarted 2023, after this paper: background citation

An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorInmune Bio, Inc.Ran2023 to 2025Enrolled12ConditionsCancer, Metastatic Castration-resistant Prostate Cancer, mCRPCArmsINKmune
NCT06443047 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Suturing Through-the-scope System Used for Prophylactic Closure of Colonic Post-ESD Defects: A Randomized Trial vs Conventional Clips That it Highlights the Importance of Suturing in Promoting Healing and Closure of the Colonic ESD Defects

TypeinterventionalSponsorIstituto Clinico HumanitasRan2025 to 2026Enrolled66ConditionsPrecancerous Lesion of ColonArmsTTS suturing system
NCT07040020 nacompletednot on this mapstarted 2025, after this paper: background citation

Water-Assisted Versus Standard ESD for Large Nonpedunculated Colorectal Polyps: a Prospective Randomized Trial

TypeinterventionalSponsorIstituto Clinico HumanitasRan2025 to 2026Enrolled122ConditionsPrecancerous LesionsArmsUnderwater ESD (U-ESD), Conventional ESD (C-ESD)
NCT07284277 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Phase Ib-II, Non-randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With modFOLFIRINOX for Front-line Treatment of Metastatic Pancreatic Adenocarcinoma (NOVOFFOX)

TypeinterventionalSponsorClinica Universidad de Navarra, Universidad de NavarraRan2025 to 2027Enrolled30ConditionsPancreatic Adenocarcinoma Metastatic, Pancreatic Ductal AdenocarcinomaArmsTTFields concomitant with modFOLFIRINOX
3 · Its place in the literature

Who cites it

9,491 citing papers in PubMed, 13 syntheses or guidelines pooled it, 16,944 citations in OpenAlex.

  1. Pooled it
  2. Prognostic value of albumin-bilirubin grade in patients with pancreatic cancer: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Pooled it
  3. HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Natural flavonoid isoorientin and its anticancer mechanisms: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Circular RNAs in ferroptosis regulation and tumor progression of gynecological and breast cancers: molecular mechanisms and therapeutic potential.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  17. Article
  18. Review
  19. Article
  20. Article

9,431 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rebecca L SiegelStrategic Director, Surveillance Information Services, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.
Kimberly D MillerEpidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.
Ahmedin JemalVice President, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.ORCID 0000-0002-0000-4111
American Cancer Society · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the National Center for Health Statistics. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2005-2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006-2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak. Of the 10 leading causes of death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was 14% higher in non-Hispanic blacks (NHBs) than non-Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13-1.15), but the racial disparity was much larger for individuals aged <65 years (DRR, 1.31; 95% CI, 1.29-1.32) compared with those aged ≥65 years (DRR, 1.07; 95% CI, 1.06-1.09) and varied substantially by state. For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged ≥65 years, whereas for those aged <65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16-3.91) and about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56-2.02), Kansas (DRR, 1.51; 95% CI, 1.25-1.81), Louisiana (DRR, 1.49; 95% CI, 1.38-1.60), Illinois (DRR, 1.48; 95% CI, 1.39-1.57), and California (DRR, 1.45; 95% CI, 1.38-1.54). Larger racial inequalities in young and middle-aged adults probably partly reflect less access to high-quality health care. CA Cancer J Clin 2018;68:7-30. © 2018 American Cancer Society.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleMiddle AgedNeoplasmsUnited StatesYoung Adultcancer casescancer statisticsdeath ratesincidencemortality

Identifiers

PMID29313949
OpenAlexW2781525129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 16 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.